Loading...

Cellular Biomedicine Group

DB:1LX
Snowflake Description

Flawless balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
1LX
DB
$320M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. The last earnings update was 65 days ago. More info.


Add to Portfolio Compare Print
1LX Share Price and Events
7 Day Returns
-1.5%
DB:1LX
0.4%
DE Biotechs
0.8%
DE Market
1 Year Returns
-7.4%
DB:1LX
-5.6%
DE Biotechs
-4.5%
DE Market
1LX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Cellular Biomedicine Group (1LX) -1.5% -0.1% -8.8% -7.4% -6.4% -
DE Biotechs 0.4% 7.3% -6.5% -5.6% 51.9% 10.5%
DE Market 0.8% 6.9% 8.1% -4.5% 10.4% 13.9%
1 Year Return vs Industry and Market
  • 1LX underperformed the Biotechs industry which returned -5.6% over the past year.
  • 1LX underperformed the Market in Germany which returned -4.5% over the past year.
Price Volatility
1LX
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Cellular Biomedicine Group undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Cellular Biomedicine Group. This is due to cash flow or dividend data being unavailable. The share price is €14.512.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Cellular Biomedicine Group's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Cellular Biomedicine Group's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:1LX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-2.20
NasdaqGS:CBMG Share Price ** NasdaqGS (2019-04-25) in USD $16.73
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.58x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 20.1x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Cellular Biomedicine Group.

DB:1LX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:CBMG Share Price ÷ EPS (both in USD)

= 16.73 ÷ -2.20

-7.62x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cellular Biomedicine Group is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Cellular Biomedicine Group is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Cellular Biomedicine Group's expected growth come at a high price?
Raw Data
DB:1LX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -7.62x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
-5.4%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.33x
Germany Market PEG Ratio Median Figure of 268 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Cellular Biomedicine Group, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Cellular Biomedicine Group's assets?
Raw Data
DB:1LX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $4.70
NasdaqGS:CBMG Share Price * NasdaqGS (2019-04-25) in USD $16.73
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.83x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:1LX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:CBMG Share Price ÷ Book Value per Share (both in USD)

= 16.73 ÷ 4.70

3.56x

* Primary Listing of Cellular Biomedicine Group.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cellular Biomedicine Group is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Cellular Biomedicine Group's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Cellular Biomedicine Group has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Cellular Biomedicine Group expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-5.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Cellular Biomedicine Group expected to grow at an attractive rate?
  • Unable to compare Cellular Biomedicine Group's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Cellular Biomedicine Group's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Cellular Biomedicine Group's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:1LX Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:1LX Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts -5.4%
DB:1LX Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 73.2%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:1LX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:1LX Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 92 -36 1
2022-12-31 25 -77 1
2021-12-31 6 -80 1
2020-12-31 3 -54 1
2019-12-31 0 -46 1
DB:1LX Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 0 -25 -39
2018-09-30 0 -24 -37
2018-06-30 0 -24 -31
2018-03-31 0 -19 -28
2017-12-31 0 -19 -25
2017-09-30 0 -18 -25
2017-06-30 0 -15 -29
2017-03-31 0 -17 -30
2016-12-31 1 -16 -28
2016-09-30 1 -15 -27
2016-06-30 2 -15 -22
2016-03-31 2 -13 -19

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Cellular Biomedicine Group is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Cellular Biomedicine Group's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:1LX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Cellular Biomedicine Group Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1LX Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -1.13 -1.13 -1.13 1.00
2022-12-31 -2.70 -2.70 -2.70 1.00
2021-12-31 -3.13 -3.13 -3.13 1.00
2020-12-31 -2.44 -2.44 -2.44 1.00
2019-12-31 -2.31 -2.31 -2.31 1.00
DB:1LX Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -2.20
2018-09-30 -2.25
2018-06-30 -1.95
2018-03-31 -1.86
2017-12-31 -1.78
2017-09-30 -1.73
2017-06-30 -2.05
2017-03-31 -2.14
2016-12-31 -2.09
2016-09-30 -2.10
2016-06-30 -1.76
2016-03-31 -1.66

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Cellular Biomedicine Group will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Cellular Biomedicine Group's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Cellular Biomedicine Group has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Cellular Biomedicine Group performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Cellular Biomedicine Group's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Cellular Biomedicine Group does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Cellular Biomedicine Group's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Cellular Biomedicine Group's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Cellular Biomedicine Group's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Cellular Biomedicine Group Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1LX Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 0.22 -38.95 13.53 24.15
2018-09-30 0.27 -37.35 13.21 22.13
2018-06-30 0.30 -30.81 12.92 19.66
2018-03-31 0.29 -27.82 13.10 16.84
2017-12-31 0.34 -25.49 13.14 14.61
2017-09-30 0.33 -24.71 12.92 13.68
2017-06-30 0.23 -29.17 12.73 12.50
2017-03-31 0.24 -30.16 12.44 12.12
2016-12-31 0.63 -28.21 12.10 11.48
2016-09-30 1.19 -27.06 12.34 10.87
2016-06-30 1.81 -21.54 13.09 10.17
2016-03-31 2.39 -19.37 13.90 8.52
2015-12-31 2.51 -19.45 13.78 7.57
2015-09-30 2.27 -19.90 13.14 6.01
2015-06-30 1.65 -17.54 11.45 4.64
2015-03-31 1.11 -14.78 9.14 4.10
2014-12-31 0.56 -12.36 7.71 3.15
2014-09-30 0.29 -9.67 7.14 2.67
2014-06-30 0.38 -8.57 6.58 2.06
2014-03-31 0.27 -7.80 6.57 1.91
2013-12-31 0.20 -11.36 9.22 2.04
2013-09-30 0.09 -11.87 8.20 3.53
2013-06-30 0.00 -11.58 7.52 4.02
2013-03-31 0.20 -11.23 7.12 3.44
2012-12-31 0.27 -7.03 3.93 3.21

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Cellular Biomedicine Group has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Cellular Biomedicine Group has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Cellular Biomedicine Group improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Cellular Biomedicine Group's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Cellular Biomedicine Group has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Cellular Biomedicine Group's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Cellular Biomedicine Group's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Cellular Biomedicine Group is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Cellular Biomedicine Group's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Cellular Biomedicine Group's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Cellular Biomedicine Group has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Cellular Biomedicine Group Company Filings, last reported 3 months ago.

DB:1LX Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 85.22 0.00 52.81
2018-09-30 100.04 0.00 67.93
2018-06-30 70.93 0.00 34.79
2018-03-31 81.32 0.00 45.56
2017-12-31 57.30 0.00 21.57
2017-09-30 49.76 0.00 16.29
2017-06-30 55.36 0.00 27.30
2017-03-31 61.22 0.00 33.36
2016-12-31 65.89 0.00 39.25
2016-09-30 70.79 0.00 44.12
2016-06-30 85.03 0.00 47.47
2016-03-31 64.72 0.00 15.67
2015-12-31 46.36 0.00 14.88
2015-09-30 56.93 0.00 20.11
2015-06-30 61.60 0.00 23.65
2015-03-31 52.67 0.00 31.14
2014-12-31 39.16 0.00 14.77
2014-09-30 36.26 0.03 9.82
2014-06-30 23.69 0.03 13.56
2014-03-31 15.95 0.03 5.96
2013-12-31 15.40 0.07 7.18
2013-09-30 14.61 0.03 3.47
2013-06-30 10.21 0.03 2.06
2013-03-31 12.51 0.03 4.86
2012-12-31 6.16 0.00 4.14
  • Cellular Biomedicine Group has no debt.
  • Cellular Biomedicine Group has no debt compared to 5 years ago when it was 0.4%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Cellular Biomedicine Group has sufficient cash runway for 1.7 years based on current free cash flow.
  • Cellular Biomedicine Group has sufficient cash runway for 1.6 years if free cash flow continues to grow at historical rates of 25.2% each year.
X
Financial health checks
We assess Cellular Biomedicine Group's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Cellular Biomedicine Group has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Cellular Biomedicine Group's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Cellular Biomedicine Group dividends.
If you bought €2,000 of Cellular Biomedicine Group shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Cellular Biomedicine Group's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Cellular Biomedicine Group's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:1LX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:1LX Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Cellular Biomedicine Group has not reported any payouts.
  • Unable to verify if Cellular Biomedicine Group's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Cellular Biomedicine Group's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Cellular Biomedicine Group has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Cellular Biomedicine Group's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Cellular Biomedicine Group afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Cellular Biomedicine Group has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Cellular Biomedicine Group's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Tony Liu
COMPENSATION $1,082,272
AGE 53
TENURE AS CEO 3.2 years
CEO Bio

Mr. Bizuo Liu, also known as Tony, has been Chief Executive Officer of Cellular Biomedicine Group Inc. since February 7, 2016 and serves as its Chief Financial Officer and served as its Secretary since January 03, 2014. Mr. Liu has been Corporate Vice President at Alibaba Group since January 2013 and is responsible for its overseas investments. Since joining Alibaba in 2009, he has held various positions including Corporate Vice President at B2B corporate investment, corporate finance and General Manager for a global ecommerce platform. He served as the Chief Financial Officer for HiChina, a subsidiary of Alibaba, a leading internet infrastructure service provider from July 2011 to December 2012. Mr. Liu spent 19 years at Microsoft Corporation where he served in a variety of finance leadership roles. He served as the General Manager of Corporate Strategy looking after Microsoft's China investment strategy and corporate strategic planning process. He was a key leader in the Microsoft corporate finance department during the 1990s as the Corporate Accounting Director. He was well recognized within Microsoft for driving an efficient worldwide finance consolidation, reporting, internal management accounting policy process and showcased Microsoft's best practices to many Fortune 500 companies in the U.S. He has been a Director of Cellular Biomedicine Group Inc. since February 2013. He obtained his Washington State CPA certificate in 1992. Mr. Liu earned a B.S. degree in Physics from Suzhou University, Suzhou, PRC and has completed MBA/MIS course work at Seattle Pacific University.

CEO Compensation
  • Tony 's compensation has been consistent with company performance over the past year.
  • Tony 's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Cellular Biomedicine Group management team in years:

1.2
Average Tenure
53
Average Age
  • The average tenure for the Cellular Biomedicine Group management team is less than 2 years, this suggests a new team.
Management Team

Tony Liu

TITLE
CEO, CFO & Director
COMPENSATION
$1M
AGE
53
TENURE
3.2 yrs

Yihong Yao

TITLE
Chief Scientific Officer
COMPENSATION
$482K
AGE
50
TENURE
3.7 yrs

Andy Chan

TITLE
Chief Legal Officer
COMPENSATION
$513K
AGE
60
TENURE
1.2 yrs

Helen Zhang

TITLE
Chief Production Officer
COMPENSATION
$447K
TENURE
1.1 yrs

Derrick Li

TITLE
Head of Strategy & Investor Relations

Sarah Kelly

TITLE
Director of Corporate Communications

Zhong Chen Kou

TITLE
Chief Scientist of Immunology

Xia Meng

TITLE
Head of Early Diagnosis & Intervention
COMPENSATION
$393K
TENURE
1.2 yrs
Board of Directors Tenure

Average tenure and age of the Cellular Biomedicine Group board of directors in years:

3.9
Average Tenure
57.5
Average Age
  • The tenure for the Cellular Biomedicine Group board of directors is about average.
Board of Directors

Terry Belmont

TITLE
Chairman of the Board
COMPENSATION
$198K
AGE
72
TENURE
3.2 yrs

Tony Liu

TITLE
CEO, CFO & Director
COMPENSATION
$1M
AGE
53
TENURE
6.2 yrs

Nadir Patel

TITLE
Independent Director
COMPENSATION
$170K
AGE
48
TENURE
4.8 yrs

Alan Au

TITLE
Independent Director
COMPENSATION
$163K
AGE
46
TENURE
4.4 yrs

Alan List

TITLE
Chair of Scientific Advisory Board
TENURE
3.8 yrs

Hansheng Zhou

TITLE
Independent Director
COMPENSATION
$163K
AGE
55
TENURE
2.8 yrs

Mike Caligiuri

TITLE
Chair of the External Advisory Board
AGE
62
TENURE
1.8 yrs

Steve Liu

TITLE
Independent Director
COMPENSATION
$135K
AGE
62
TENURE
5.5 yrs

Guotong Xu

TITLE
Member of Scientific Advisory Board
COMPENSATION
$138K
AGE
60
TENURE
2.4 yrs

Scott Antonia

TITLE
Member of Scientific Advisory Board
TENURE
4 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
15. Feb 19 Sell Yihong Yao Individual 26. Oct 18 26. Oct 18 -194 €11.20 €-2,173
15. Feb 19 Sell Yihong Yao Individual 27. Nov 18 27. Dec 18 -388 €15.84 €-6,072
15. Feb 19 Sell Andrew Chan Individual 26. Oct 18 26. Oct 18 -168 €11.20 €-1,882
15. Feb 19 Sell Andrew Chan Individual 27. Nov 18 27. Dec 18 -356 €15.84 €-5,571
15. Feb 19 Sell Bizuo Liu Individual 26. Oct 18 26. Oct 18 -875 €11.20 €-9,801
15. Feb 19 Sell Bizuo Liu Individual 27. Nov 18 27. Dec 18 -1,750 €15.84 €-27,387
X
Management checks
We assess Cellular Biomedicine Group's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Cellular Biomedicine Group has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer and orthopedic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), a genetically modified T-cell receptors (TCRs), and next generation neoantigen-reactive tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases. The company’s CAR-T products include CD20 for use in anti-tumor activities; CD22, a surface maker highly expressed in B cell malignancies in hairy cell leukemia; and B-cell maturation antigen therapies for treating refractory multiple myeloma in patients. It also develops NKG2D CAR therapies for use in NK cell signaling; alpha fetoprotein TCR-T therapies for treating hepatocellular carcinoma; tumor infiltrating lymphocyte therapies for treating immunogenic cancers; and knee osteoarthritis therapies, including AlloJoin therapy, which is in a Phase I clinical trial, as well as Re-Join that has completed the Phase IIb clinical trial. In addition, it engages in biopharmaceutical businesses, including research and development, technical support, technical service, and technology transfer activities in biomedical technology field; manufacturing non-food, pharmaceutical polypeptides, and medical devices; and the wholesale of cosmetics, sanitary products, and biological agents. The company has a strategic licensing and collaboration agreement with Novartis Pharma AG to manufacture and supply their CAR-T cell therapy Kymriah in China. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in New York, New York.

Details
Name: Cellular Biomedicine Group, Inc.
1LX
Exchange: DB
Founded: 2001
$287,169,827
19,118,916
Website: http://www.cellbiomedgroup.com
Address: Cellular Biomedicine Group, Inc.
1345 Avenue of Americas,
15th Floor,
New York,
New York, 10105,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS CBMG Common Stock Nasdaq Global Select US USD 11. Feb 2013
DB 1LX Common Stock Deutsche Boerse AG DE EUR 11. Feb 2013
Number of employees
Current staff
Staff numbers
193
Cellular Biomedicine Group employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/25 22:37
End of day share price update: 2019/04/25 00:00
Last estimates confirmation: 2019/04/17
Last earnings filing: 2019/02/19
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.